6xqu
From Proteopedia
(Difference between revisions)
m (Protected "6xqu" [edit=sysop:move=sysop]) |
|||
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
==Extreme malleability of the SARS-CoV-2 3CL Mpro active site cavity facilitates binding of clinical antivirals: Prospects for repurposing existing drugs and ramifications for inhibitor design== | ==Extreme malleability of the SARS-CoV-2 3CL Mpro active site cavity facilitates binding of clinical antivirals: Prospects for repurposing existing drugs and ramifications for inhibitor design== | ||
| - | <StructureSection load='6xqu' size='340' side='right'caption='[[6xqu]]' scene=''> | + | <StructureSection load='6xqu' size='340' side='right'caption='[[6xqu]], [[Resolution|resolution]] 2.20Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XQU OCA]. For a <b>guided tour on the structure components</b> use [ | + | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XQU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6XQU FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2Å</td></tr> |
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=U5G:boceprevir+(bound+form)'>U5G</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xqu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xqu OCA], [https://pdbe.org/6xqu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xqu RCSB], [https://www.ebi.ac.uk/pdbsum/6xqu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xqu ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Virus protease 3D structures|Virus protease 3D structures]] | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Current revision
Extreme malleability of the SARS-CoV-2 3CL Mpro active site cavity facilitates binding of clinical antivirals: Prospects for repurposing existing drugs and ramifications for inhibitor design
| |||||||||||
